193 related articles for article (PubMed ID: 32087595)
1. Current concepts in breast cancer genomics: An evidence based review by the CGC breast cancer working group.
Geiersbach KB; Chen H; Emmadi R; Haskell GT; Lu X; Liu YJ; Swisshelm K
Cancer Genet; 2020 Jun; 244():11-20. PubMed ID: 32087595
[TBL] [Abstract][Full Text] [Related]
2. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
[TBL] [Abstract][Full Text] [Related]
3. A decision support framework for genomically informed investigational cancer therapy.
Meric-Bernstam F; Johnson A; Holla V; Bailey AM; Brusco L; Chen K; Routbort M; Patel KP; Zeng J; Kopetz S; Davies MA; Piha-Paul SA; Hong DS; Eterovic AK; Tsimberidou AM; Broaddus R; Bernstam EV; Shaw KR; Mendelsohn J; Mills GB
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25863335
[TBL] [Abstract][Full Text] [Related]
4. An Integrative Approach for Identifying Network Biomarkers of Breast Cancer Subtypes Using Genomic, Interactomic, and Transcriptomic Data.
Firoozbakht F; Rezaeian I; D'agnillo M; Porter L; Rueda L; Ngom A
J Comput Biol; 2017 Aug; 24(8):756-766. PubMed ID: 28650678
[TBL] [Abstract][Full Text] [Related]
5. Insights into the theranostic value of precision medicine on advanced radiotherapy to breast cancer.
Jiang M; Yang J; Li K; Liu J; Jing X; Tang M
Int J Med Sci; 2021; 18(3):626-638. PubMed ID: 33437197
[TBL] [Abstract][Full Text] [Related]
6. Identification of a 6-gene signature for the survival prediction of breast cancer patients based on integrated multi-omics data analysis.
Mo W; Ding Y; Zhao S; Zou D; Ding X
PLoS One; 2020; 15(11):e0241924. PubMed ID: 33170908
[TBL] [Abstract][Full Text] [Related]
7. The horizon of precision medicine in breast cancer: fragmentation, alliance, or reunification?
Andre F; Vicier C; Delaloge S
Am Soc Clin Oncol Educ Book; 2014; ():e5-10. PubMed ID: 24857146
[TBL] [Abstract][Full Text] [Related]
8. Molecular Genomic Testing for Breast Cancer: Utility for Surgeons.
Fayanju OM; Park KU; Lucci A
Ann Surg Oncol; 2018 Feb; 25(2):512-519. PubMed ID: 29159748
[TBL] [Abstract][Full Text] [Related]
9. Extensive Transcriptomic and Genomic Analysis Provides New Insights about Luminal Breast Cancers.
Tishchenko I; Milioli HH; Riveros C; Moscato P
PLoS One; 2016; 11(6):e0158259. PubMed ID: 27341628
[TBL] [Abstract][Full Text] [Related]
10. Genomic Alterations Associated with Recurrence and TNBC Subtype in High-Risk Early Breast Cancers.
Wilson TR; Udyavar AR; Chang CW; Spoerke JM; Aimi J; Savage HM; Daemen A; O'Shaughnessy JA; Bourgon R; Lackner MR
Mol Cancer Res; 2019 Jan; 17(1):97-108. PubMed ID: 30171174
[TBL] [Abstract][Full Text] [Related]
11. Identification of Novel Breast Cancer Subtype-Specific Biomarkers by Integrating Genomics Analysis of DNA Copy Number Aberrations and miRNA-mRNA Dual Expression Profiling.
Li D; Xia H; Li ZY; Hua L; Li L
Biomed Res Int; 2015; 2015():746970. PubMed ID: 25961039
[TBL] [Abstract][Full Text] [Related]
12. Current advances in the diagnosis and personalized treatment of breast cancer: lessons from tumor biology.
Kern R; Correa SC; Scandolara TB; Carla da Silva J; Pires BR; Panis C
Per Med; 2020 Sep; 17(5):399-420. PubMed ID: 32804054
[TBL] [Abstract][Full Text] [Related]
13. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
[TBL] [Abstract][Full Text] [Related]
14. Precision medicine in breast cancer: genes, genomes, and the future of genomically driven treatments.
Stover DG; Wagle N
Curr Oncol Rep; 2015 Apr; 17(4):15. PubMed ID: 25708799
[TBL] [Abstract][Full Text] [Related]
15. Integration of somatic mutation, expression and functional data reveals potential driver genes predictive of breast cancer survival.
Suo C; Hrydziuszko O; Lee D; Pramana S; Saputra D; Joshi H; Calza S; Pawitan Y
Bioinformatics; 2015 Aug; 31(16):2607-13. PubMed ID: 25810432
[TBL] [Abstract][Full Text] [Related]
16. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.
Groisberg R; Hong DS; Holla V; Janku F; Piha-Paul S; Ravi V; Benjamin R; Kumar Patel S; Somaiah N; Conley A; Ali SM; Schrock AB; Ross JS; Stephens PJ; Miller VA; Sen S; Herzog C; Meric-Bernstam F; Subbiah V
Oncotarget; 2017 Jun; 8(24):39254-39267. PubMed ID: 28424409
[TBL] [Abstract][Full Text] [Related]
17. Toward personalized management in bladder cancer: the promise of novel molecular taxonomy.
Eich ML; Dyrskjøt L; Netto GJ
Virchows Arch; 2017 Aug; 471(2):271-280. PubMed ID: 28429075
[TBL] [Abstract][Full Text] [Related]
18. Interplay Between Genetic and Epigenetic Changes in Breast Cancer Subtypes.
Dumitrescu RG
Methods Mol Biol; 2018; 1856():19-34. PubMed ID: 30178244
[TBL] [Abstract][Full Text] [Related]
19. Genomic Profiling in Node-Positive ER-Positive Early Breast Cancer: Can Tumor Biology Guide Locoregional Therapy?
Garrido-Castro AC; Winer EP
J Natl Cancer Inst; 2017 Apr; 109(4):. PubMed ID: 28376163
[No Abstract] [Full Text] [Related]
20. Clinical Risk During the Evaluation of Genomic Risk for Hormone-Sensitive Breast Cancer: Ignoring Valuable Data.
Khaki AR; Gadi VK; Prasad V
J Natl Compr Canc Netw; 2019 Dec; 17(12):1456-1458. PubMed ID: 31805524
[No Abstract] [Full Text] [Related]
[Next] [New Search]
